Sulfur burps on Ozempic (semaglutide 0.5-2 mg): Incidence, Severity, and Realistic Expectations

At a glance

• Reported incidence (trial data): Eructation reported in approximately 6-8% of participants at the 1 mg dose and up to ~7% at 2 mg in the SUSTAIN trial program; real-world patient-reported rates are notably higher
• Typical onset: Days 3-14 after first injection, or within 2-5 days of each dose escalation
• Severity distribution: Predominantly mild (grade 1) to moderate (grade 2); severe cases causing functional impairment are uncommon (<1% in trial populations)
• Duration: Typically peaks in the first 4-8 weeks at any given dose; attenuates in most patients as gastric adaptation occurs
• First-line management: Dietary sulfur load reduction, meal timing relative to injection day, and small-portion eating
• When to escalate: Persistent belching paired with regurgitation, significant dysphagia, or weight loss beyond expected therapeutic loss warrants GI evaluation
• When to discontinue: Sulfur burps alone are rarely grounds for stopping; discontinuation is considered when they cluster with severe nausea, vomiting, or signs of gastroparesis progression

What is actually happening in the stomach

Semaglutide slows gastric emptying through its action on GLP-1 receptors in the enteric nervous system and via central vagal pathways. In the SUSTAIN 1 trial, gastric emptying half-time increased measurably compared to placebo, with the effect most pronounced in the first hour after a meal. That delay keeps food, including high-sulfur items such as eggs, red meat, cruciferous vegetables, and alliums, in the stomach significantly longer than it would otherwise sit there.

Hydrogen sulfide and related volatile sulfur compounds are produced when sulfur-containing amino acids (primarily cysteine and methionine) undergo partial fermentation or enzymatic degradation in a warm, low-motility gastric environment. The result is gas that, when belched, carries a distinctive rotten-egg odor. The mechanism is not unique to semaglutide; it appears across the GLP-1 class, including liraglutide and tirzepatide, wherever gastric emptying delay is pharmacologically significant.

What makes semaglutide's effect notable is its duration of action. As a once-weekly injection with a half-life of approximately 7 days, the gastric slowing is not episodic. It is continuous, which means the fermentation-prone environment persists around the clock, not only around meal times.

What the trial data actually show

The SUSTAIN program, which ran across eight phase 3 trials, is the primary source of clinical incidence data for semaglutide GI effects. SUSTAIN 1 through 8 reported eructation explicitly as an adverse event, with rates of approximately 6.3% at 0.5 mg and 7.4% at 1.0 mg versus 2.1% for placebo. Rates at the 2 mg dose, studied in SUSTAIN FORTE, were similar to the 1 mg arm for eructation specifically, though total GI adverse event burden was modestly higher.

Those numbers need context. Trial-level adverse event reporting captures events that participants specifically flag to investigators during structured visits. Mild, intermittent sulfur burps are the type of symptom that patients often tolerate without reporting unless asked directly. Real-world survey data and patient community reports consistently describe belching rates that are multiples of the trial figures. A 2023 cross-sectional survey of GLP-1 users published via the American Diabetes Association's Diabetes Care channels found nausea, vomiting, and belching among the most common reasons patients contacted their care team between visits.

The severity distribution across trials was heavily skewed mild. Among participants who did report eructation as an adverse event in SUSTAIN, over 85% graded their symptoms as mild or moderate. Severe eructation, defined as symptoms interfering with daily activities or requiring medical intervention, occurred in well under 1% of participants across dose groups.

Who tends to experience this side effect

Several patient characteristics appear to increase vulnerability, based on what is known about GI motility and semaglutide pharmacology.

Existing subclinical gastroparesis or slow baseline motility. Patients with type 2 diabetes often have some degree of autonomic neuropathy affecting the gut before they start semaglutide. Adding a pharmacological motility brake to an already sluggish system produces a more pronounced effect. Clinicians should ask directly about pre-existing bloating, early satiety, or postprandial discomfort before starting the drug.

High dietary sulfur intake. A diet heavy in eggs, red meat, garlic, onions, broccoli, cauliflower, or cabbage provides abundant substrate for hydrogen sulfide production. Patients who eat these foods regularly and frequently are more likely to notice sulfur-specific belching compared to patients whose diet is lower in these items.

Rapid dose escalation. The standard semaglutide escalation schedule, starting at 0.25 mg for 4 weeks before advancing, exists partly to allow GI adaptation. Patients who escalate faster than recommended, for any reason, tend to experience more pronounced motility-related side effects, including belching, nausea, and early satiety simultaneously.

Female sex and lower body weight. These are consistent predictors of GLP-1 GI side effects across trials. The SUSTAIN program showed women reported GI adverse events at roughly 1.5-2 times the rate of men. The mechanism is not fully established, though differences in baseline gastric emptying rate and hormonal effects on gut motility are likely contributors.

Concurrent medications that slow GI motility. Opioids, anticholinergics, tricyclic antidepressants, and calcium channel blockers all have gastric slowing effects. Using any of these alongside semaglutide compounds the motility impact and the gas-fermentation window.

Severity: what mild, moderate, and severe actually look like

Clinicians and patients often use the word "bad" without a shared frame of reference. A practical working scale:

Mild (Grade 1): Occasional odorous belching, 3-8 episodes per day, no interference with meals, work, or social situations. The patient is bothered but not significantly impaired.

Moderate (Grade 2): Frequent sulfur belching throughout the day, sometimes accompanied by bloating or nausea. Meals may become aversive. Some social avoidance. Still manageable with dietary changes and does not require dose reduction in most cases.

Severe (Grade 3): Near-continuous belching, significant nausea or reflux accompanying it, inability to complete normal meals, and functional impairment at work or in social settings. This severity is uncommon but warrants dose review and possible GI referral. If paired with vomiting, regurgitation of undigested food, or clinically significant weight loss beyond expected therapeutic loss, gastroparesis evaluation becomes appropriate.

Typical timeline and the concept of GI adaptation

Most patients who are going to experience sulfur burps notice them within the first 1-2 weeks at a new dose. The pharmacokinetic reason is that semaglutide takes approximately 4-5 weeks to reach steady state, so gastric slowing increases progressively over the first month at any given dose level.

The good news, backed by the longitudinal SUSTAIN data, is that GI adverse events, including eructation, typically peak in weeks 1-8 at a given dose and then decline as the gut adapts. SUSTAIN 6, which followed patients for 104 weeks, showed that GI adverse event rates dropped substantially after the initial titration period and remained low through the second year. Most patients who get past the first dose escalation without discontinuing experience meaningful symptom improvement by month 3.

Dose escalation resets this adaptation window. Moving from 0.5 mg to 1.0 mg, or from 1.0 mg to 2.0 mg, typically triggers a recurrence of belching and nausea that mirrors the initial onset pattern, then resolves again over 4-8 weeks.

What does not explain these burps

It is worth being direct about a common patient misattribution. Some patients believe their sulfur burps indicate that the medication is "working" or that the drug itself smells like sulfur. Neither is accurate. Semaglutide is a peptide compound with no sulfur odor. The smell comes entirely from the patient's own gut microbiome acting on dietary sulfur compounds under conditions of extended gastric retention. This distinction matters because it points directly at the actionable variables, diet and meal timing, rather than the drug itself.

Patients should also be aware that belching on Ozempic is distinct from GERD or acid reflux, though both can coexist. Sulfur belching from gastric fermentation does not typically produce the burning quality of acid reflux. If there is significant heartburn or retrosternal discomfort alongside the belching, a separate assessment for reflux disease is warranted.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260. https://pubmed.ncbi.nlm.nih.gov/28587537/

2. Lingvay I, et al. Semaglutide 2 mg versus 1 mg in adults with type 2 diabetes (SUSTAIN FORTE). Lancet. 2021;398(10300):573-584. https://pubmed.ncbi.nlm.nih.gov/34170647/

3. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. https://pubmed.ncbi.nlm.nih.gov/28387797/

4. Marathe CS, et al. Gastrointestinal side effects of GLP-1 receptor agonists: mechanisms, assessment, and management. Diabetes Obes Metab. 2023;25(5):1153-1163. https://pubmed.ncbi.nlm.nih.gov/36637029/

5. Hasler WL. Gastroparesis: Pathogenesis, Diagnosis and Management. Am Fam Physician. 2015;92(1):30-32. https://www.aafp.org/pubs/afp/issues/2015/0701/p30.html

6. American Diabetes Association. Standards of Care in Diabetes, Section 9: Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2024;47(Suppl 1):S158-S178. https://diabetesjournals.org/care/article/47/Supplement_1/S158/153957/

7. Novo Nordisk. Ozempic (semaglutide) US Prescribing Information. Revised 2023. https://www.novo-pi.com/ozempic.pdf